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Dear editor
A recent review by Salvo et al published in Patient Preference and Adherence 
concerned dapagliflozin, and was titled “Patient considerations in the management of 
type 2 diabetes – critical appraisal of dapagliflozin”.1 Having read the article, I do not 
consider it to be a critical appraisal of dapagliflozin. Thus, after comparing dapagliflozin 
with other oral antidiabetic medications, the authors concluded that “Dapagliflozin’s 
noted blood pressure reduction, weight loss, and low potential to cause hypoglycemia 
are advantageous, when compared with currently available oral medications”.1 This 
statement is not supported by the content of the review and/or the literature. 
In their review of the efficacy of dapagliflozin, Salvo et al have provided little or 
no evidence that dapagliflozin reduces blood pressure. Dapagliflozin monotherapy was 
initially suggested to reduce blood pressure by a small amount at 24 weeks.2 However, 
the ability of dapagliflozin to reduce blood pressure is small, and is not always statisti-
cally significant.3,4 Thus, the reduction of blood pressure with dapagliflozin cannot be 
considered to be notable, and is unlikely to have any clinical significance.
Secondly, Salvo et al do provide some evidence of weight loss with dapagliflozin, 
of up to 4.65 kg,1 but do not critically appraise the significance of this. Although it 
is well established that being overweight or obese is a risk factor for diabetes and 
cardiovascular disease, it has not been shown that reducing weight in subjects with 
diabetes reduces long term cardiovascular outcomes. Thus, the Look AHEAD (Action 
for Health In Diabetes) trial in overweight or obese subjects with type 2 diabetes, 
compared an intensive lifestyle intervention to promote weight loss to diabetes sup-
port and education (control group). This trial was abandoned after 9.6 years, on the 
basis of a futility analysis for the primary outcome, which was a composite of death 
from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospi-
talization for angina.5 The futility in Look AHEAD was shown despite an initial 8.6% 
body weight loss (from a baseline of approximately 101 kg) and reduction in glycated 
hemoglobin of approximately 0.6% (from a baseline of about 7.3%) in the intensive 
lifestyle intervention group.5 Given the findings of Look AHEAD, it is unlikely that 
a reduction in body weight of up to 4.65 kg with dapagliflozin is alone going to be 
beneficial in type 2 diabetes.
Also, Salvo et al suggest that the weight loss with dapagliflozin is an advantage 
over other oral medications in treating subjects with type 2 diabetes.1 Weight gain 
is observed with the sulfonylureas and the thiazolidinediones (eg, rosiglitazone). 
Thus, the weight loss with dapagliflozin may be an advantage over these medicines. 
However, the dipeptidylpeptidase inhibitors (gliptins) do not cause weight gain, and 
usually cause weight loss eg, saxagliptin.6 Glucagon-like peptide 1 receptor (GLP-1R) 
agonists, which are administered subcutaneously, also cause weight loss eg, exenatide.7 
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It seems to me, that these groups of anti-diabetic drugs, and 
their ability to cause weight loss, should have been part of 
any critical appraisal of dapagliflozin.
Thirdly, Salvo et al have suggested that dapagliflozin has 
a lesser ability to cause hypoglycemia than other oral anti-
diabetes medicines, and provided evidence that dapagliflozin 
has a low potential to cause hypoglycemia compared to the 
sulfonylureas (glipazide, glimepride),1 but not to other oral 
anti-diabetic medications. Thus, there is no evidence avail-
able to support dapagliflozin having lower hypoglycemia 
potential than metformin or GLP-1R agonists/gliptins, all of 
which have a lesser propensity to cause hypoglycemia than 
the sulfonylureas, eg, exenatide,7 saxagliptin.6 Also, defini-
tive evidence for any low potential to cause hypoglycemia 
can only be obtained from comparative trials, and (at present) 
there are no published studies comparing metformin or the 
GLP-1R agonists/gliptins to dapagliflozin, let alone compar-
ing their potential to cause hypoglycemia. 
The authors did conclude that “long-term clinical trials 
and post-marketing studies are needed to further investigate 
dapagliflozin’s cardiovascular profile, and its impact on mor-
bidity and mortality”,1 but this seems somewhat understated 
to me. To date, cardiovascular events with dapagliflozin 
have only been evaluated in subjects with type 2 diabetes, 
not having major cardiovascular disease. In their submis-
sion to the US Food and Drug Administration (FDA) about 
dapagliflozin, Bristol-Myers Squibb included a meta-analysis 
of cardiovascular events in their clinical program, in which 
only 37% of subjects had a history of cardiovascular disease 
(excluding hypertension).8 In this group, the cardiovascular 
events (cardiovascular death, stroke, myocardial infarction, 
hospitalization of unstable angina) were low; probably 
because the enrolled population was not high risk.8 In this 
low risk group, cardiovascular events occurred in 1.99% of 
the comparator group, compared to 1.64% per subject year in 
the dapagliflozin, and this was not significantly different.8 
The multicenter trial that will eventually be able to evalu-
ate the cardiovascular safety of dapagliflozin, is the effect 
of dapagliflozin on the incidence of cardiovascular events 
(DECLARE-TIMI58).9 DECLARE-TIMI58 is a Phase III 
trial recruiting 22,200 subjects with type 2 diabetes and high 
cardiovascular risk subjects.9 In this trial, dapagliflozin or 
placebo will be added to the subjects’ current anti-diabetes 
medicines, and the primary outcome measure is the compos-
ite of cardiovascular death, myocardial infarction or ischemic 
stroke in subjects with type 2 diabetes.9 DECLARE-TIMI58 
is due to be completed in April 2019.9 By this time, it will be 
about 5 years since the FDA approved dapagliflozin for use 
in subjects with type 2 diabetes. Thus, dapagliflozin will be 
available for 5 years without proven cardiovascular efficacy 
or safety. It seems to me, that dapagliflozin should not have 
been registered, until DECLARE-TIMI58 was complete, 
and cardiovascular safety established. This point should 
have been considered by Salvo et al in a critical appraisal 
of dapagliflozin. 
In conclusion, dapagliflozin does not have a noted ability 
to reduce blood pressure. However, dapagliflozin does cause 
weight loss and have a low potential to cause hypoglycemia, 
but this is not necessarily an advantage, as other medicines 
available for the treatment of type 2 diabetes also cause 
weight loss and have a low propensity to cause hypoglycemia. 
Most importantly, the cardiovascular clinical outcome study 
DECLARE-TIMI58 being undertaken with dapagliflozin will 
not report for 5 years, and thus dapagliflozin will be avail-
able for the treatment of type 2 diabetes for 5 years without 
proven cardiovascular efficacy or safety.
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Dear editor
In response to the letter by Doggrell regarding our 
recent publication entitled, “Patient considerations in the 
management of type 2 diabetes – critical appraisal of dapa-
gliflozin”, we would first like to express appreciation for 
the interest in our publication as well as the opportunity to 
respond.1 The overall intent of our review of dapagliflozin 
was to provide a critique of the available primary literature 
for this newly available medication (approved in the US 
during the time of manuscript preparation), however, we did 
not intend to be “critical” in the negative sense described 
by Doggrell. We contend that our review provides a fair 
and unbiased overview of the available primary literature 
and does not over or understate any of the findings. As 
mentioned by Doggrell, there is very limited comparative 
effectiveness research with dapagliflozin, and within diabe-
tes therapies in general. The intention of the publication was 
not to “compare” available therapies but rather to present 
the available evidence for dapagliflozin and succinctly sum-
marize the advantages and disadvantages of this compound, 
in the context of other therapies, with special attention to 
patient considerations. This is similar to the approach taken 
by the American Diabetes Association (ADA) and European 
Association for the Study of Diabetes (EASD) consensus 
algorithm which advises clinicians to consider second line 
therapies (following metformin) based upon risk of hypo-
glycemia, weight gain, cost, and major side effects.2 
In reference to blood pressure lowering potential, our 
review includes four studies that demonstrate blood pressure 
lowering with dapagliflozin (-2.1 to -6.4 mmHg systolic 
blood pressure and -1.7 to -3.3 mmHg diastolic blood 
pressure).3–6 We acknowledge that the clinical significance of 
this blood pressure reduction is unknown at this time given 
the limitations of blood pressure reduction as a surrogate for 
clinical outcomes and the differences observed in outcomes 
between antihypertensive medication classes. However, as 
with other patient considerations, note this as a potentially 
favorable characteristic for patients with concomitant dia-
betes and hypertension. 
In regards to the weight loss (up to 4.65 kg) demonstrated 
with dapagliflozin and the futility of the Look AHEAD study, 
we would like to acknowledge that there are benefits of 
weight loss other than cardiovascular outcomes and also com-
ment on limitations of the Look AHEAD data.7 As previously 
mentioned, our article focuses on patient considerations in the 
management of type 2 diabetes. In working with thousands 
of overweight and obese patients over the past fifteen years 
our observation has been that there is patient preference for 
medications that contribute to weight loss. Beyond prefer-
ence, the ADA EASD algorithm supports weight loss as a 
consideration in selecting second line therapy.2 In the Look 
AHEAD trial, the patient population had an average duration 
of diabetes of 14 years, by study-end the absolute difference 
in weight loss between intervention and control groups was 
around 2.5%, and the overall cardiovascular event rate was 
much lower than anticipated.7 These factors likely contrib-
uted to the lack of cardiovascular benefit observed with the 
weight loss intervention in this study. Additionally, despite 
these limitations, patients in the intervention group demon-
strated reductions in urinary incontinence, sleep apnea, and 
depression and improvements in quality of life, mobility, and 
physical functioning.7 Though cardiovascular outcomes were 
not improved, these non-cardiovascular benefits are certainly 
important patient considerations when selecting therapy. 
We too look forward to the eventual availability of results 
from the DECLARE-TIMI58 trial and acknowledge that those 
findings will undoubtedly strengthen the understanding of 
dapagliflozin’s cardiovascular impact and subsequent place 
in therapy. The United States Food and Drug Administration 
requires that new drug sponsors provide data supporting car-
diovascular safety prior to the approval of any new therapy for 
type 2 diabetes.8 The FDA recommendations are to include 
patients in Phase II and III studies who have a longer duration 
of diabetes, are elderly, and have some degree of renal dys-
function.8 Dapagliflozin’s available evidence includes patients 
with these characteristics and has demonstrated no increased 
cardiovascular risk. While it is certainly ideal to use medi-
cations with cardiovascular benefit (so far only metformin) 
and those with a long track record of cardiovascular safety; 
unfortunately, these options are currently very limited. 
We maintain that dapagliflozin represents a promising 
new therapeutic approach to the treatment of type 2 diabetes 
that is a viable second line (or beyond) therapy option for 
select patients.
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